Technical Analysis for ELOX - Eloxx Pharmaceuticals Inc
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
11.1 | 5.01% | 0.5300 |
ELOX closed up 5.01 percent on Friday, January 25, 2019, on 71 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It was able to find support at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | N/A | Up | Down |
| See historical ELOX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Support | Bullish | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Strong but Oversold | Other | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Strong, Oversold and Reversal Signs | Reversal | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 50 DMA Support | Bullish | 5.01% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 5.01% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Sector: Healthcare
- Industry: Biotechnology
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.
RTT Medical Specialties Branches Of Biology Biopharmaceutical Cystic Fibrosis Treatment Of Cystic Fibrosis Channelopathies
RTT Medical Specialties Branches Of Biology Biopharmaceutical Cystic Fibrosis Treatment Of Cystic Fibrosis Channelopathies
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 19.5 |
| 52 Week Low | 6.25 |
| Average Volume | 34,167 |
| 200-Day Moving Average | 0.0 |
| 50-Day Moving Average | 10.4196 |
| 20-Day Moving Average | 13.1605 |
| 10-Day Moving Average | 13.963 |
| Average True Range | 1.8743 |
| ADX | 19.61 |
| +DI | 33.555 |
| -DI | 40.377 |
| Chandelier Exit (Long, 3 ATRs ) | 13.8771 |
| Chandelier Exit (Short, 3 ATRs ) | 15.482899999999999 |
| Upper Bollinger Band | 18.9285 |
| Lower Bollinger Band | 7.3925 |
| Percent B (%b) | 0.32 |
| BandWidth | 87.656244 |
| MACD Line | 0.6579 |
| MACD Signal Line | 1.244 |
| MACD Histogram | -0.5861 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 12.2100 | ||||
| Resistance 3 (R3) | 12.0867 | 11.5933 | 12.0250 | ||
| Resistance 2 (R2) | 11.5933 | 11.3107 | 11.6550 | 11.9633 | |
| Resistance 1 (R1) | 11.3467 | 11.1360 | 11.4700 | 11.4700 | 11.9016 |
| Pivot Point | 10.8533 | 10.8533 | 10.9150 | 10.9150 | 10.8533 |
| Support 1 (S1) | 10.6067 | 10.5707 | 10.7300 | 10.7300 | 10.2984 |
| Support 2 (S2) | 10.1133 | 10.3960 | 10.1750 | 10.2367 | |
| Support 3 (S3) | 9.8667 | 10.1133 | 10.1750 | ||
| Support 4 (S4) | 9.9900 |
